Q1 2023
Analytical Development
Positioning MIRA for an initial IND filing in Q3 2024
| MIRA1a | Pre-Clinical | IND | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
MIRA1aAnxiety & Cognitive Decline in early stage dementia patients |
Pre-Clinical Phase complete
|
IND Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
MIRA1aNeuropathic Pain |
Pre-Clinical Phase complete
|
IND Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
MIRA Pharmaceuticals Timeline
Pre-clinical work is underway and should be completed by Q1’24
Q2 2023
Q3 2023
- NonGMP
- Micronucleus Assay
- Metabolic Profiling
- ^MTD/7D DRF Rat
- ^MTD/7D DRF Dog
Q4 2023
- ^^GMP
- *Cardiovascular Study Dog
- **Respiratory Study Rat
- ***hERG
- Neurobehavioral Evaluation Rat
Q4 2023-Q1 2024
- Dog 28-day Toxicology
- Rat 28-day Toxicology
Q3 2024
Anxiety & Cognitive Decline in the Elderly
- IND
Q4 2024
Anxiety & Cognitive Decline in the Elderly
- Phase 1 (30 days post IND submission)
Q1 2025
Anxiety & Cognitive Decline in the Elderly
- Phase 2
Q2 2025
Q3 2025
Neuropathic Pain
- IND